The inhibition of Nbs1-dependent ATR activation in p53-deficient colorectal cancer cell (HT29) increased sensitivity to oxaliplatin and cisplatin chemotherapeutic agents through a reduction in proliferation, increase in sub-G1 cell population and cleaved-caspase3 after 72 h treatment with the inhibitor CBP-93872 [151]. The gene discussed is ATR; the disease is colorectal cancer.